NCT06363110View on ClinicalTrials.gov

An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States

CompletedOBSERVATIONAL
Enrollment

1,400

Participants

Timeline

Start Date

April 10, 2024

Primary Completion Date

June 24, 2024

Study Completion Date

June 24, 2024

Conditions
Chronic Heart Failure With Reduced Ejection Fraction
Interventions
DRUG

Vericiguat (Verquvo, BAY1021189)

Follow clinical practice/administration

Trial Locations (1)

07981

Bayer, Whippany

Sponsors

Lead Sponsor

Bayer
All Listed Sponsors
lead

Bayer

INDUSTRY

NCT06363110 - An Observational Study to Learn More About Vericiguat Treatment Patterns and Its Safety in People With Chronic Heart Failure With Reduced Ejection Fraction in Routine Medical Care in the United States | Biotech Hunter | Biotech Hunter